抗HCV抗体和抗TP抗体筛查试验的假阳性问题及对策研究进展

doi:10.3969/j.issn.1673-8640.2015.12.002

摘要/Abstract

摘要：

酶联免疫吸附试验(ELISA)和化学发光免疫分析法(CLIA)检测抗丙型肝炎病毒(HCV)抗体和抗梅毒螺旋体(TP)抗体存在一定比例的假阳性,故需经确证试验方能报告阳性结果。确定特定检测试剂(系统)在特定人群筛查试验结果的阳性预测值达95%的信号/临界值(S/CO)比值,可作为尽可能降低ELISA 或CLIA检测抗HCV抗体或抗TP抗体假阳性率和经济合理应用确证试验的对策。

关键词: 抗丙型肝炎病毒抗体, 抗梅毒螺旋体抗体, 筛查试验, 假阳性, 确证试验

Abstract:

There is a certain proportion of false positivity in screening assay for detecting anti-hepatitis C virus (HCV)antibody and anti-treponema pallidum(TP)antibody by enzyme-linked immunosorbent assay (ELISA) or chemiluminescence immunoassay (CLIA). Therefore, it is required to report positive results by confirmation assay . It is an alternative strategy for reducing false positive rate as far as possible in detecting anti-HCV antibody and anti-TP antibody by ELISA and CLIA and making the application of confirmation assay economic and rational by determining the signal-to-cut off (S/CO) ratio, when the positive predictive value of screening assay results reaches 95% with certain detection reagent (system) and in certain population.

Key words: Anti-hepatitis C virus antibody, Anti-treponema pallidum antibody, Screening assay, False positivity, Confirmation assay

中图分类号:

R446.61

陈存存综述, 范列英审校. 抗HCV抗体和抗TP抗体筛查试验的假阳性问题及对策研究进展[J]. 检验医学, 2015, 30(12): 1167-1174.

CHEN Cuncun, FAN Lieying.. The study progress of false positivity in screening assay for detecting anti-HCV antibody and anti-TP antibody and its strategy[J]. Laboratory Medicine, 2015, 30(12): 1167-1174.

参考文献 41

[1]	MOHD HANAFIAH K, GROEGER J, FLAXMAN AD, et al.Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence[J]. Hepatology, 2013, 57(4): 1333-1342.
[2]	CDC. Public health service inter-agency guidelines for screening donors of blood, plasma, organs, tissues, and semen for evidence of hepatitis B and hepatitis C[J]. MMWR Recomm Rep, 1991, 40(RR-4): 1-17.
[3]	张瑞,李金明. 丙型肝炎病毒感染临床检测程序的建立及结果报告与解释[J].中华检验医学杂志,2010,33(10):990-992.
[4]	KLEINMAN S, ALTER H, BUSCH M, et al.Increased detection of hepatitis C virus (HCV)-infected blood donors by a multiple-antigen HCV enzyme immunoassay[J]. Transfusion, 1992, 32(9): 805-813.
[5]	CONRY-CANTILENA C, VANRADEN M, GIBBLE J, et al.Routes of infection,viremia, and liver disease in blood donors found to have hepatitis C virus infection[J]. N Engl J Med, 1996, 334(26): 1691-1696.
[6]	HYAMS KC, RIDDLE J, RUBERTONE M, et al.Prevalence and incidence of hepatitis C virus infection in the US military: a seroepidemiologic survey of 21,000 troops[J]. Am J Epidemiol, 2001, 153(8): 764-770.
[7]	ALTER MJ, KRUSZON-MORAN D, NAINAN OV, et al.The prevalence of hepatitis C virus infection in the United States, 1988 through 1994[J]. N Engl J Med, 1999, 341(8): 556-562.
[8]	MONTECALVO MA, LEE MS, DEPALMA H, et al.Seroprevalence of human immunodeficiency virus-1, hepatitis B virus, and hepatitis C virus in patients having major surgery[J]. Infect Control Hosp Epidemiol, 1995, 16(11):627-632.
[9]	GOETZ AM, NDIMBIE OK, WAGENER MM, et al.Prevalence of hepatitis C infection in health care workers affiliated with a liver transplant center[J]. Transplantation, 1995, 59(7):990-994.
[10]	ROOMEAJ, HADLER JL, THOMAS AL, et al.Hepatitis C virus infection among firefighters, emergency medical technicians, and paramedics-selected locations, United States, 1991- 2000[J]. MMWR Morb Mortal Wkly Rep, 2000, 49(29): 660-665.
[11]	GUNN RA, MURRAY PJ, ACKERS ML, et al.Screening for chronic hepatitis B and C virus infections in an urban sexually transmitted disease clinic: rationale for integrating services[J]. Sex Transm Dis, 2001, 28(3):166-170.
[12]	CDC. Recommendations for preventing transmission of infections among chronic hemodialysis patients[J]. MMWR Recomm Rep, 2001, 50(RR-5):1-43.
[13]	ROUET F, DELEPLANCQUE L, MBOUMBA BB, et al.Usefulness of a fourth generation ELISA assay for the reliable ide.pngication of HCV infection in HIV-positive adults from Gabon (Central Africa)[J].PLoS One, 2015, 10(1):e0116975.
[14]	MULLIS CE, LAEYENDECKER O, REYNOLDS SJ, et al.High frequency of false-positive hepatitis C virus enzyme-linked immunosorbent assay in Rakai, Uganda[J].Clin Infect Dis, 2013, 57(12): 1747-1750.
[15]	任芙蓉,龚晓燕,李京京,等. 献血员丙型肝炎病毒抗体酶免疫法检测试剂的测量值与其真阳性的相关性[J].中华肝脏病杂志,2005,13(4):255-258.
[16]	万大朋,刘胜武. 化学发光免疫分析法检测丙型肝炎抗体的临床评价[J]. 中外医疗, 2014, 34(20):193-194.
[17]	ALTER MJ, KUHNERT WL, FINELLI L,et al.Guidelines for laboratory testing and result reporting of antibody to hepatitis C virus. Centers for Disease Control and Prevention[J]. MMWR Recomm Rep, 2003, 52(RR-3): 1-13.
[18]	CHAUDHARY RK, JACOBSEN H.Performance of third-generation confirmatory tests for detection of antibody to hepatitis C virus[J]. J Clin Microbiol, 1994, 32(10):2606-2608.
[19]	ZAAIJER HL, VRIELINK H, VAN EXEL-OEHLERS PJ, et al. Confirmation of hepatitis C infection: a comparison of five immunoblot assays[J].Transfusion, 1994,34(7): 603-607.
[20]	COUROUCÉ AM, NOEL L, BARIN F, et al.A comparative evaluation of the sensitivity of five anti-hepatitis C virus immunoblot assays[J]. Vox Sang, 1998, 74(4): 217-224.
[21]	PAWLOTSKY JM.Use and interpretation of virological tests for hepatitis C[J]. Hepatology, 2002, 36(5 Suppl 1): S65-S73.
[22]	ROTH WK, BUSCH MP, SCHULLER A, et al.International survey on NAT testing of blood donations: expanding implementation and yield from 1999 to 2009[J]. Vox Sang, 2012, 102(1): 82-90.
[23]	HOURFAR MK, JORK C, SCHOTTSTEDT V, et al.Experience of German Red Cross blood donor services with nucleic acid testing: results of screening more than 30 million blood donations for human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus[J]. Transfusion, 2008, 48(8): 1558-1566.
[24]	DUFOUR DR, TALASTAS M, FERNANDEZ MD, et al.Low-positive anti-hepatitis C virus enzyme immunoassay results: an important predictor of low likelihood of hepatitis C infection[J]. Clin Chem, 2003, 49(3): 479-486.
[25]	CONTRERAS AM, OCHOA-JIMENEZ RJ, KERSHENOBICH D, et al.Guideline for interpretation and report of the antibody to hepatitis C virus. Grupo de Desarrollo de la Guía[J]. Rev Invest Clin, 2012, 64(6 Pt 2): 641-678.
[26]	MORSHED MG, SINGH AE.Recent trends in the serologic diagnosis of syphilis[J]. Clin Vaccine Immunol, 2015, 22(2): 137-147.
[27]	YOUNG H, PRYDE J, DUNCAN L, et al.The Architect Syphilis assay for antibodies to Treponema pallidum: an automated screening assay with high sensitivity in primary syphilis[J]. Sex Transm Infect, 2009, 85(1): 19-23.
[28]	傅均星,周潇,曾铁兵. 基因重组抗原ELISA法在梅毒螺旋体抗体检测中的评价[J]. 南华大学学报:医学版, 2004,32(3):305-306.
[29]	刘贵育,王明丽. TP-ELISA诊断梅毒螺旋体感染的可行性评价[J].安徽医科大学学报,2004,39(2):150-152.
[30]	王露楠,邓巍,李金明. 梅毒螺旋体感染不同血清学诊断方法的临床评价[J].中华检验医学杂志,2002,25(6):352-353.
[31]	刘勇, 肖玲, 刘敏. ELISA 法筛查临床样本中梅毒螺旋体抗体假阳性结果分析[J].医学信息,2010,(2):152-153.
[32]	陈兰兰,邵燕玲,王巧凤,等. 自动化梅毒螺旋体抗体初筛实验的研究[J]. 中华检验医学杂志,2013,36(10):891-894.
[33]	WANG LN, LI JM.Evaluation of immunoglobulin M and G Western blot and ELISA for screening antibodies to Treponema pallidum in blood donors[J]. Sex Transm Dis, 2009, 36(7):413-416.
[34]	武艳霞,卢改会. 孕产妇及新生儿血清 TPPA 假阳性在临床的影响[J]. 中国实用医药,2013,8(21):76.
[35]	陈红霞. 肿瘤患者与老年患者的TPPA假阳性分析[J].江西医学检验,2007,25(3):288.
[36]	季德成,李晓平,董春雷,等. ELISA 法检测老年人梅毒抗体易产生假阳性分析[J].放射免疫学杂志,2005,18(3):239-240.
[37]	熊继红,张秀明,卢建强,等. 雅培I2000sr CMIA 法筛查梅毒螺旋体特异性抗体的测量阈值探讨[J]. 现代检验医学杂志,2012,27(6):105-106.
[38]	朱鸿,赵乙洁. 化学发光法检测特异性梅毒抗体的 S/CO 值的实验室评价[J]. 大连医科大学学报,2013,35(3):298-299.
[39]	王伦善,吕蓉,盛琪琪,等. 梅毒抗体酶联免疫吸附试验S/CO比值与TPPA结果的相关性研究[J]. 中国输血杂志,2011, 24(2):126-127.
[40]	方伟祯,谢文锋,丁睿,等. 300例住院患者梅毒血清学试验阳性结果分析[J]. 中国实用医药,2011,6(3):9-11.
[41]	Centers for Disease Control and Prevention(CDC). Discordant results from reverse sequence syphilis screening-five laboratories, United States, 2006-2010[J]. MMWR Morb Mortal Wkly Rep, 2011, 60(5): 133-137.